Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1982 Sep;37(3):1285–1288. doi: 10.1128/iai.37.3.1285-1288.1982

Stimulation of Resistance of Immunocompromised Mice by a Muramyl Dipeptide Analog

Yasuaki Osada 1, Masao Mitsuyama 2, Kensuke Matsumoto 1, Tsutomu Une 1, Tsuyoshi Otani 1, Hidemasa Ogawa 1, Kikuo Nomoto 2
PMCID: PMC347677  PMID: 6752024

Abstract

L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, enhanced resistance against Escherichia coli and Candida albicans infections in aged mice and younger adult mice whose defense mechanism(s) had been depressed by X-ray irradiation or by treatment with cyclophosphamide.

Full text

PDF
1286

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buhles W. C., Jr, Shifrine M. Adjuvant protection against bacterial infection in granulocytopenic mice. J Infect Dis. 1977 Jul;136(1):90–95. doi: 10.1093/infdis/136.1.90. [DOI] [PubMed] [Google Scholar]
  2. Chedid L., Parant M., Parant F., Audibert F., Lefrancier F., Choay J., Sela M. Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)--poly(L-lysine) carrier. Proc Natl Acad Sci U S A. 1979 Dec;76(12):6557–6561. doi: 10.1073/pnas.76.12.6557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Collis C. H. Lung damage from cytotoxic drugs. Cancer Chemother Pharmacol. 1980;4(1):17–27. doi: 10.1007/BF00255453. [DOI] [PubMed] [Google Scholar]
  5. Cummings N. P., Pabst M. J., Johnston R. B., Jr Activation of macrophages for enhanced release of superoxide anion and greater killing of Candida albicans by injection of muramyl dipeptide. J Exp Med. 1980 Dec 1;152(6):1659–1669. doi: 10.1084/jem.152.6.1659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DONALDSON D. M., MARCUS S., GYI K. K., PERKINS E. H. The influence of immunization and total body x-irradiation on intracellular digestion by peritoneal phagocytes. J Immunol. 1956 Mar;76(3):192–199. [PubMed] [Google Scholar]
  7. Dunger D. B., Malpas J. S., Graham-Pole J. R., Sandland M. R., Stansfeld A. G., Freeman J. E. The use of four-drug combination chemotherapy (D.A.V.E.) in the treatment of advanced Wilms' tumour. Cancer Chemother Pharmacol. 1981;5(4):211–215. doi: 10.1007/BF00434386. [DOI] [PubMed] [Google Scholar]
  8. FISHMAN M., SCHECHMEISTER I. L. The effect of ionizing radiation on phagocytosis and the bactericidal power of the blood. II. The effect of radiation on ingestion and digestion of bacteria. J Exp Med. 1955 Mar 1;101(3):275–290. doi: 10.1084/jem.101.3.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Golomb H. M., Hanauer S. B. Infectious complications associated with hairy cell leukemia. J Infect Dis. 1981 May;143(5):639–643. doi: 10.1093/infdis/143.5.639. [DOI] [PubMed] [Google Scholar]
  10. Guiot H. F., van der Meer J. W., van Furth R. Selective antimicrobial modulation of human microbial flora: infection prevention in patients with decreased host defense mechanisms by selective elimination of potentially pathogenic bacteria. J Infect Dis. 1981 May;143(5):644–654. doi: 10.1093/infdis/143.5.644. [DOI] [PubMed] [Google Scholar]
  11. Kireszenbaum F., Ferraresi R. W. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect Immun. 1979 Jul;25(1):273–278. doi: 10.1128/iai.25.1.273-278.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Krahenbuhl J. L., Sharma S. D., Ferraresi R. W., Remington J. S. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice. Infect Immun. 1981 Feb;31(2):716–722. doi: 10.1128/iai.31.2.716-722.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Matsumoto K., Ogawa H., Kusama T., Nagase O., Sawaki N., Inage M., Kusumoto S., Shiba T., Azuma I. Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice. Infect Immun. 1981 May;32(2):748–758. doi: 10.1128/iai.32.2.748-758.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Matsumoto T., Miake S., Mitsuyama M., Takeya K., Nomoto K. Augmented resistance to Listeria monocytogenes in mice at an early stage of aging. J Clin Lab Immunol. 1979 Apr;2(1):55–58. [PubMed] [Google Scholar]
  15. NELSON E. L., BECKER J. R. The effect of whole-body x irradiation on the bactericidal activity of phagocytic cells. I. Survival of Pseudomonas aeruginosa within phagocytes from peritoneal exudates of mice. J Infect Dis. 1959 Jan-Feb;104(1):13–19. doi: 10.1093/infdis/104.1.13. [DOI] [PubMed] [Google Scholar]
  16. Osada Y., Mitsuyama M., Une T., Matsumoto K., Otani T., Satoh M., Ogawa H., Nomoto K. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections. Infect Immun. 1982 Jul;37(1):292–300. doi: 10.1128/iai.37.1.292-300.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Taylor R. E., Smith I. E., Ford H. T., Bryant B. M., Casey A. J., Smyth J. F. Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung. Cancer Chemother Pharmacol. 1980;4(4):271–273. doi: 10.1007/BF00255273. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES